Tiziana Life Sciences Doses First Patients in Phase 2a ALS Trial of Intranasal Foralumab

Tiziana Life Sciences Ltd. (TLSA) said on Sept. 28, 2026, that the first three participants received their initial dose of intranasal foralumab in the Phase 2a Healey ALS MyMatch BANYAN trial, which evaluates the therapy in patients with amyotrophic lateral sclerosis. The trial is part of the Healey ALS Platform Trial, a multi-arm, adaptive study designed to test multiple investigational treatments simultaneously. Foralumab is a fully human anti-CD3 monoclonal antibody delivered intranasally. The company did not disclose interim efficacy or safety data. Enrollment figures, dosing schedule and expected data readout timing were not specified in the announcement.